文献速递血管炎

新发巨细胞动脉炎患者血管炎症消退:RIGA研究

Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

RIGA研究为观察性研究,纳入88例新发活动性大血管型巨细胞动脉炎(LV-GCA)患者,分别接受泼尼松单药、联合甲氨蝶呤或托珠单抗治疗,基线与随访行[18F]FDG PET/CT评估血管炎症。结果显示PETVAS总体从18.9降至8.0(P<0.001),三种治疗均能控制血管炎症,托珠单抗的激素节约效应最强。

要点

  • LV-GCA治疗后PETVAS总体从18.9降至8.0(P<0.001)。
  • 甲氨蝶呤与托珠单抗组PETVAS降幅数值上高于泼尼松单药组。
  • 托珠单抗激素节约效应最强,支持初始联合治疗理念。

核心结论

  • 治疗LV-GCA可抑制主动脉及其主要分支的血管炎症。
  • 泼尼松、甲氨蝶呤与托珠单抗对血管炎症的控制相似,托珠单抗显示强激素节约效应,支持初始联合治疗。

研究设计与样本

  • 观察性研究,纳入88例新发活动性LV-GCA患者,基线及随访行[18F]FDG PET/CT,由独立读者以PETVAS评估主动脉及主要分支。
  • 27例接受泼尼松单药(PRED),42例联合甲氨蝶呤(MTX),19例联合托珠单抗(TOC)。

主要发现

  • 总体人群PETVAS从18.9降至随访时8.0单位(P<0.001)。
  • PETVAS变化在MTX组(-12.3单位)或TOC组(-11.7单位)数值上高于PRED组(-8.7单位)。
  • PRED、MTX和TOC组平均累积泼尼松剂量分别为5637、4418和2984 mg(P=0.002)。
  • 随访PET/CT时停用糖皮质激素的风险比:MTX较PRED为6.77(95%CI: 1.01, 45.29;P=0.049),TOC较PRED为16.25(95%CI: 2.60, 101.73;P=0.003)。

临床怎么用

  • 对LV-GCA可采用[18F]FDG PET/CT的PETVAS动态评估血管炎症。
  • 托珠单抗联合方案具有显著激素节约效应,可考虑用于初始联合治疗。

局限性

  • 为观察性研究,未报告随机化或盲法。
  • 原文未报告各组基线特征及PETVAS组间差异的统计学检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Efficacy evaluation of GCA treatment is primarily based on non-specific symptoms and laboratory markers. We aimed to assess the change in vascular inflammation in patients with large vessel (LV)-GCA under different treatments using [18F]FDG PET/CT. METHODS: Observational study on patients with new-onset, active LV-GCA starting treatment with either prednisolone monotherapy (PRED) or combination with MTX or tocilizumab (TOC). All patients underwent baseline and follow-up PET/CT. The aorta and its major branches were assessed using PET vascular activity score (PETVAS) by independent readers. Cumulative glucocorticoid doses and cessation of glucocorticoid treatment were documented in all patients. RESULTS: We included 88 LV-GCA patients, 27 were treated with PRED, 42 with MTX and 19 with TOC. PETVAS decreased from 18.9-8.0 units at follow-up in the overall population (P <0.001). PETVAS changes were numerically higher in patients receiving MTX (-12.3 units) or TOC (-11.7 units) compared with PRED (-8.7). Mean cumulative prednisolone dosages were 5637, 4418 and 2984 mg in patients treated with PRED, MTX and TOC (P =0.002). Risk ratios for glucocorticoid discontinuation at the time of follow-up PET/CT were 6.77 (95% CI: 1.01, 45.29; P =0.049) and 16.25 (95% CI: 2.60, 101.73; P =0.003) for MTX and TOC users compared with PRED users. CONCLUSION: Treatment of LV-GCA inhibits vascular inflammation in the aorta and its major branches. While similar control of vascular inflammation was achieved with PRED, MTX and TOC treatments, TOC showed a strong glucocorticoid sparing effect, supporting the concept of initial combination therapy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Schönau V, Roth J, Tascilar K, et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology (Oxford). 2021. PMID: 33831144. doi:10.1093/rheumatology/keab332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。